LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Increased monocyte level is a risk factor for radiological progression in patients with early fibrotic interstitial lung abnormality

    Andrew Achaiah / Paul Lyon / Emily Fraser / Peter Saunders / Rachel Hoyles / Rachel Benamore / Ling-Pei Ho

    ERJ Open Research, Vol 8, Iss

    2022  Volume 3

    Abstract: Background Interstitial lung abnormalities (ILA) are specific spatial patterns on computed tomography (CT) scan potentially compatible with early interstitial lung disease. A proportion will progress; management involves risk stratification and ... ...

    Abstract Background Interstitial lung abnormalities (ILA) are specific spatial patterns on computed tomography (CT) scan potentially compatible with early interstitial lung disease. A proportion will progress; management involves risk stratification and surveillance. Elevated blood monocyte levels have been shown to associate with progression of idiopathic pulmonary fibrosis. The aims of the present study were: 1) to estimate the proportion of “early fibrotic” (EF)-ILAs (reticular±ground-glass opacities, excluding traction bronchiectasis and honeycombing) on CT scans of patients attending all-indications thoracic CTs, and proportion demonstrating radiological progression; and 2) to explore association between peripheral blood leukocyte levels and ILA progression. Methods We analysed all thoracic CT reports in individuals aged 45–75 years performed between January 2015 and December 2020 in one large teaching hospital (Oxford, UK) to identify patient CT reports consistent with EF-ILA. CT-contemporaneous blood leukocyte counts were examined to explore contribution to progression and all-cause mortality, using multivariate Cox regression. Results 40 711 patients underwent thoracic CT imaging during this period. 1259 (3.1%) demonstrated the EF-ILA pattern (mean±sd age 65.4±7.32 years; 735 (47.8%) male). EF-ILA was significantly associated with all-cause mortality (hazard ratio 1.87, 95% CI 1.25–2.78; p=0.002). 362 cases underwent at least one follow-on CT. Radiological progression was observed in 157 (43.4%) cases: increase in reticulation n=51, new traction bronchiectasis n=84, honeycombing n=22. Monocyte count, neutrophil count, monocyte:lymphocyte ratio, neutrophil:lymphocyte ratio and “systemic inflammatory response index” were significantly associated with radiological progression. Conclusion 3.1% of subjects requiring thoracic CT during a 6-year period demonstrated EF-ILA. Monocyte levels and blood leukocyte-derived indexes were associated with radiological progression and could indicate which patients may require ...
    Keywords Medicine ; R
    Subject code 610
    Language English
    Publishing date 2022-07-01T00:00:00Z
    Publisher European Respiratory Society
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: Nintedanib for non-IPF progressive pulmonary fibrosis

    Lavanya Raman / Iain Stewart / Shaney L. Barratt / Felix Chua / Nazia Chaudhuri / Anjali Crawshaw / Michael Gibbons / Charlotte Hogben / Rachel Hoyles / Vasilis Kouranos / Jennifer Martinovic / Sarah Mulholland / Katherine J. Myall / Marium Naqvi / Elisabetta A. Renzoni / Peter Saunders / Matthew Steward / Dharmic Suresh / Muhunthan Thillai /
    Athol U. Wells / Alex West / Jane A. Mitchell / Peter M. George

    ERJ Open Research, Vol 9, Iss

    12-month outcome data from a real-world multicentre observational study

    2023  Volume 2

    Abstract: Background Nintedanib slows lung function decline for patients with non-idiopathic pulmonary fibrosis progressive pulmonary fibrosis (PPF) in clinical trials, but the real-world safety and efficacy are not known. Methods In this retrospective cohort ... ...

    Abstract Background Nintedanib slows lung function decline for patients with non-idiopathic pulmonary fibrosis progressive pulmonary fibrosis (PPF) in clinical trials, but the real-world safety and efficacy are not known. Methods In this retrospective cohort study, standardised data were collected from patients in whom nintedanib was initiated for PPF between 2019 and 2020 through an early-access programme across eight centres in the United Kingdom. Rate of lung function change in the 12 months pre- and post-nintedanib initiation was the primary analysis. Symptoms, drug safety, tolerability and stratification by interstitial lung disease subtype and computed tomography pattern were secondary analyses. Results 126 patients were included; 67 (53%) females; mean±sd age 60±13 years. At initiation of nintedanib, mean forced vital capacity (FVC) was 1.87 L (58% predicted) and diffusing capacity of the lung for carbon monoxide (DLCO) was 32.7% predicted. 68% of patients were prescribed prednisolone (median dose 10 mg) and 69% were prescribed a steroid-sparing agent. In the 12 months after nintedanib initiation, lung function decline was significantly lower than in the preceding 12 months: FVC −88.8 mL versus −239.9 mL (p=0.004), and absolute decline in DLCO −2.1% versus −6.1% (p=0.004). Response to nintedanib was consistent in sensitivity and secondary analyses. 89 (71%) out of 126 patients reported side-effects, but 86 (80%) of the surviving 108 patients were still taking nintedanib at 12 months with patients reporting a reduced perception of symptom decline. There were no serious adverse events. Conclusion In PPF, the real-world efficacy of nintedanib replicated that of clinical trials, significantly attenuating lung function decline. Despite the severity of disease, nintedanib was safe and well tolerated in this real-world multicentre study.
    Keywords Medicine ; R
    Subject code 610
    Language English
    Publishing date 2023-03-01T00:00:00Z
    Publisher European Respiratory Society
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant

    Najib M Rahman / Robert Wilson / John M Wrightson / Nayia Petousi / Ian Pavord / Mona Bafadhel / Stephen Chapman / Rachel Hoyles / William Flight / Emily Fraser / Annabel Nickol / Dinesh Addala / Radhika Banka / Robert Hallifax / Anny Sykes / John Park / Patrick Elder / Anand Sundaralingam / Maxine Hardinge /
    Chris D Turnbull / Sarah B Evans / Rachel Lardner / Henry V Bettinson / Peter Saunders / Alastair Moore / Nicholas P Talbot / Maria Tsakok / Anastasia Fries / Simon Couillard / James Melhorn / Timothy Hinks / Andrew Achaiah / Benedict M L Porter / Oliver Smith / Eihab Bedawi / Hannah Danbury / Eric Douglas / Ling Pei Ho / Vishal Nathwani / Shefaly Patel / Hannah Laurenson-Schafer / Francesca Roxburgh

    BMJ Open Respiratory Research, Vol 8, Iss

    2021  Volume 1

    Keywords Medicine ; R ; Diseases of the respiratory system ; RC705-779
    Language English
    Publishing date 2021-12-01T00:00:00Z
    Publisher BMJ Publishing Group
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top